Focused On-demand Library for Zinc finger CCCH domain-containing protein 14

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6PJT7

UPID:

ZC3HE_HUMAN

Alternative names:

Mammalian suppressor of tau pathology-2; Renal carcinoma antigen NY-REN-37

Alternative UPACC:

Q6PJT7; A8MY46; B4DXU8; B4DZW7; B4E2H4; G3V5R4; Q6MZU4; Q6PJ32; Q6PUI6; Q6PUI8; Q86TQ5; Q86TW0; Q86TW1; Q8NCT6; Q8NCZ3; Q8TDE2; Q9HAC9; Q9Y5A0

Background:

Zinc finger CCCH domain-containing protein 14, also known as Mammalian suppressor of tau pathology-2 and Renal carcinoma antigen NY-REN-37, plays a crucial role in poly(A) tail length control in neuronal cells by binding to polyadenosine RNA oligonucleotides. Its unique function underscores its importance in post-transcriptional regulation, a key process in gene expression.

Therapeutic significance:

This protein's involvement in Intellectual developmental disorder, autosomal recessive 56, highlights its potential as a target for therapeutic intervention. Understanding the role of Zinc finger CCCH domain-containing protein 14 could open doors to potential therapeutic strategies, offering hope for patients and advancing the field of genetic disorders.